Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test aims to spot multiple cancers early

NCT ID NCT05181826

Diagnosis Sponsor: Helio Genomics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to measure how sensitive and specific the test is, and to identify conditions that could cause false results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multi-analyte Blood Test
What this could lead to
If successful, this blood test could help detect multiple cancers early, potentially improving treatment outcomes and survival rates.
What could go wrong
This is an observational study focused on test development, not a treatment. The test may not prove accurate enough for widespread use, and false positives or negatives are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2019

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease will eligible to participate in this study.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 2.1.1 Age 18 years or older. 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. . Exclusion Criteria: 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded. 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chronic obstructive pulmonary disease cirrhosis of liver COPD, severe early onset diabetes mellitus hepatitis hepatitis B virus infection hepatitis C virus infection Hepatitis, Chronic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Chronic hepatitis COPD Diabetes Hepatitis B Hepatitis C Liver cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allina Health, Virginia Piper Cancer Institute

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Liver Center of Texas

    RECRUITING

    Dallas, Texas, 75234, United States

  • Methodist Hospital

    RECRUITING

    Richardson, Texas, 75082, United States

  • Methodist LeBonheur Healthcare

    RECRUITING

    Memphis, Tennessee, 38104, United States

  • Torrance Memorial Physician Network - Cancer Care

    ACTIVE_NOT_RECRUITING

    Redondo Beach, California, 90277, United States

  • VPCI Oncology Research

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Virginia Piper Cancer Institute Mercy Hospital-Unity Campus

    RECRUITING

    Fridley, Minnesota, 55432, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.